+1 Recommend
2 collections

      Call for Papers: Digital Diagnostic Techniques

      Submit here before August 31, 2024

      About Pathobiology5.0 Impact Factor I 7.7 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

      Submit here before July 31, 2024

      About Oncology Research and Treatment: 2.4 Impact Factor I 3.3 CiteScore I 0.495 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Comprehensive Analysis of the Relationship between Cuproptosis-Related Gene GCSH and Prognosis, Tumor Microenvironment Infiltration, and Therapy Response in Endometrial Cancer


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Introduction: Cuproptosis is a novel form of cell death regulated by protein lipoylation and implicated in mitochondrial metabolism. However, further research is needed to explore the influence of the cuproptosis-related gene γ-glutamylcysteine synthetase (GCSH) on the prognosis of endometrial cancer (EC), the tumor immune microenvironment, and therapeutic response. Methods: The differential expression of GCSH between EC and normal tissues was analyzed using multiple public databases. Additionally, cancer and adjacent tissues were prospectively collected from 17 EC patients, and immunohistochemical analysis was performed to further investigate GCSH expression differences. The relationship between GCSH and the prognosis and clinicopathological characteristics of EC patients was evaluated, and a nomogram was constructed to predict patient survival based on GCSH expression. Subsequently, Gene set variation analysis was used to explore the potential biological functions of GCSH in EC. The impact of GCSH on the tumor microenvironment (TME) was estimated. Finally, the effect of GCSH on the response to immunotherapy and chemotherapeutic drugs in EC was investigated. Results: The expression of GCSH was significantly upregulated in EC. High GCSH expression was associated with poor prognosis in EC patients. Enrichment analysis revealed an association between high GCSH and immune suppression. Furthermore, high GCSH was found to be associated with a non-inflamed TME, leading to decreased infiltration levels of immune cells. Lastly, it was observed that patients with high GCSH exhibited insensitivity to both immunotherapy and chemotherapeutic drugs. Conclusion: This study revealed the role of GCSH in TME, response to therapy, and clinical prognosis in EC, which provided novel insights for the therapeutic application in EC.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          Profiling Tumor Infiltrating Immune Cells with CIBERSORT.

          Tumor infiltrating leukocytes (TILs) are an integral component of the tumor microenvironment and have been found to correlate with prognosis and response to therapy. Methods to enumerate immune subsets such as immunohistochemistry or flow cytometry suffer from limitations in phenotypic markers and can be challenging to practically implement and standardize. An alternative approach is to acquire aggregative high dimensional data from cellular mixtures and to subsequently infer the cellular components computationally. We recently described CIBERSORT, a versatile computational method for quantifying cell fractions from bulk tissue gene expression profiles (GEPs). Combining support vector regression with prior knowledge of expression profiles from purified leukocyte subsets, CIBERSORT can accurately estimate the immune composition of a tumor biopsy. In this chapter, we provide a primer on the CIBERSORT method and illustrate its use for characterizing TILs in tumor samples profiled by microarray or RNA-Seq.
            • Record: found
            • Abstract: found
            • Article: not found

            ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.

            The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11-13 December 2014 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert panel prepared three clinically relevant questions about endometrial cancer relating to the following four areas: prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. Results of this consensus conference, together with a summary of evidence supporting each recommendation, are detailed in this article. All participants have approved this final article.
              • Record: found
              • Abstract: not found
              • Article: not found

              GSVA: gene set variation analysis for microarray and RNA-seq data


                Author and article information

                S. Karger AG
                May 2024
                12 October 2023
                : 102
                : 5
                : 368-381
                [a ]Department of Gynecologic Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China
                [b ]Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, China
                [c ]Clinical Center and Key Lab of Intestinal and Colorectal Diseases of Hubei Province, Wuhan, China
                [d ]Department of General Medical, Zhongnan Hospital of Wuhan University, Wuhan, China
                Author notes
                *Fan Wang, niehhy@whu.edu.cn, Jun Fang, xhfangjun@163.com, Qiu Zhao, zhaoqiuwhu@163.com
                534018 Oncology 2024;102:368–381
                © 2023 S. Karger AG, Basel
                : 11 July 2023
                : 31 August 2023
                Page count
                Figures: 7, Pages: 14
                Supported by Wuhan University Zhongnan Hospital difficult disease diagnosis and treatment capacity improvement project (oncology) (Grant No. ZLYNXM202017), the Program of Excellent Doctoral (postdoctoral) of Zhongnan Hospital Wuhan University (Grant Nos. ZNYB2019003 and ZNYB2022003), Special Project of knowledge Innovation of Wuhan Science and Technology Bureau (Dawning project) (Grant No. KYXM2022007).
                Research Article

                Prognosis,Endometrial cancer,GCSH,Cuproptosis,Tumor microenvironment,Immunotherapy
                Prognosis, Endometrial cancer, GCSH, Cuproptosis, Tumor microenvironment, Immunotherapy


                Comment on this article